A5022149616- Safe Handling of Antineoplastic Drugs
- CNS Lymphoma Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Neutropenia and Cancer Infections
- Pediatric health and respiratory diseases
- Health Systems, Economic Evaluations, Quality of Life
- Statistical Methods in Clinical Trials
- Cancer Genomics and Diagnostics
- Nosocomial Infections in ICU
- Clostridium difficile and Clostridium perfringens research
Advocate Health Care
2024
Aurora St. Luke's Medical Center
2024
Aurora Health Care
2021-2023
The treatment of cancer is associated with high risk for toxicity and cost. Strategies to enhance the value, quality, safety care are often managed independently one another. Oncology stewardship a potential framework unify these efforts outcomes. This landscape survey establishes baseline information on oncology in United States.
Abstract Background Evaluations of oral vancomycin prophylaxis (OVP) against Clostridioides difficile have been reported in stem cell transplant populations with short follow-up periods. The longest known duration standardized post-OVP is 90 days within an allogeneic population. In 2017, we implemented OVP 125 mg twice daily autologous (ASCT) recipients beginning the day admission and continued until discharge. Methods Patients who received ASCT our institution between 1 January 2012 31...
Purpose: The impact of central nervous system (CNS) prophylaxis in diffuse large B-cell lymphoma (DLBCL) is contentious. CNS International Prognostic Index (IPI) calculator offers prognostic guidance identifying those patients who may be at highest risk disease progression or relapse to the CNS. However, it unclear whether this tool has guided clinician decision-making a real-world setting. Studies have suggested that not offer clinically significant benefit terms preventing progression....
372 Background: Melphalan hydrochloride is a primary agent used in the conditioning regimen for autologous stem cell transplant indications including multiple myeloma and lymphoma. Brand Alkeran labelling indicates drug concentration must not exceed 0.45 mg/mL should be given over minimum 15 minutes but infused its entirety within 60 from preparation. Caution provided as data has shown loss of potency by 1% every 10 after melphalan dilution. Time constraints often require dose being divided...